abstract |
A modified release pharmaceutical composition (controlled release, sustained release, and / or sustained release) of the R (+) enantiomer (RPPX) of pramipexole, and said composition as a neurodegenerative disease or mitochondrial dysfunction or Disclosed are methods for use in treating those associated with increased oxidative stress. [Selection] Figure 1 |